berberine

Overview

Berberine (BBR) is a naturally occurring isoquinoline alkaloid belonging to the protoberberine class, found in several medicinal plants including Berberis, Coptis chinensis, and Coscinium fenestratum. It is characterized by a distinctive yellow color and a quaternary ammonium structure that enables intercalation into nucleic acids, binding to G-quadruplex (G4) DNA structures, and interaction with a broad spectrum of protein targets. Historically significant in traditional Asian medicine for its antimicrobial and anti-inflammatory properties, berberine has attracted sustained scientific attention for its pleiotropic pharmacological effects spanning metabolic regulation, anti-inflammatory signaling, and antineoplastic activity.

Mechanistically, berberine modulates multiple oncogenic and inflammatory cascades including the PI3K/Akt signaling pathway, the β-catenin/TCF4 axis, nuclear factor kappa B (NF-κB) signaling, and the CD44/JAK2/STAT3 signaling pathway. Its ability to intercalate into DNA and compete for nucleic acid-binding sites makes it a structurally versatile scaffold for targeting both protein–DNA and protein–protein interactions relevant to cancer and infectious disease. These properties, combined with a favorable safety profile relative to synthetic chemotherapeutics, have positioned berberine as a compound of significant translational interest across oncology, immunology, and antiviral research.

Focus of Latest Publications

Recent publications have continued to examine berberine as a bioactive compound with broad therapeutic potential, especially in metabolic, neurodegenerative, inflammatory, and cancer-related settings. In a mouse model of hyperglycemia-induced neurodegeneration, berberine was investigated for its neuroprotective effects and was proposed to act through modulation of Nrf2 expression. A separate Alzheimer’s-focused formulation study developed a berberine-loaded nanoemulsion for intranasal nose-to-brain delivery, reporting improved brain targeting, reduced reactive oxygen species, restoration of mitochondrial membrane potential in SH-SY5Y cells, and behavioral improvement in scopolamine-induced cognitive, depressive, and motor deficits.

Several studies also explored berberine in cancer and cell survival pathways. In colorectal cancer cells, berberine dose-dependently inhibited viability, promoted apoptosis, and suppressed DNA damage repair by upregulating SOX17 and inactivating the β-catenin/TCF4 pathway, with PIM3 identified as a downstream mediator. In an Ehrlich ascites carcinoma mouse model, berberine enhanced cisplatin efficacy, reduced tumor volume and cell counts, and ameliorated cisplatin-associated hepato-renal toxicity, alongside downregulation of Akt1, Axl, Mertk, and Gas6, indicating effects on the PI3K/Akt signaling pathway and efferocytosis.

Berberine also appeared in studies of inflammatory and infectious disease-related mechanisms. In a zebrafish model of TNBS-induced enteritis, berberine was identified among Huoxiang-Huanglian components predicted to bind ODC1, and the treatment was associated with reduced IL-1β, TNF-α, MDA, NLRP3, CASP1, NF-κB p65, and ODC1, while increasing IL-10, superoxide dismutase, and AhR expression. In a computational study of Coscinium fenestratum alkaloids against SARS-CoV-2 host factors, berberine was among the alkaloids considered in network pharmacology and docking analyses, although tembetarine emerged as the lead candidate rather than berberine.

Additional work has focused on formulation and comparative bioactivity. A liposomal release study compared two berberine-loaded liposomal formulations under controlled shear conditions and found that drug-membrane affinity influenced release under mild shear, while higher mechanical stress reduced formulation differences; the study also showed that a colloidal matrix could suppress release through a shear-shielding mechanism. In an anti-adipogenic phytochemical study, berberine served as the positive control against which a diarylpentanoid isolate was compared, with the isolate showing stronger inhibition of lipid accumulation in 3T3-L1 preadipocytes than berberine.

Key Publications

NEWJun Berberine attenuates hyperglycemia induced neurodegeneration in mice by modulation of Nrf2 expression. (Molecular biology reports, 2026, PMID 42334690): "Berberine (BBR), a natural compound used in the treatment of diabetes and diabetes-associated cognitive dysfunction (DACD), although the underlying mode of action remains largely unknown."
Jun Bioactivity-guided isolation of anti-adipogenic diarylpentanoids from Rhamnoneuron balansae. (Fitoterapia, 2026, PMID 42229863): "Compound 15 demonstrated the highest potency, with an EC50 value of 2.17 μM, about 3.3-fold lower than that of the positive control berberine (EC50 = 7.24 μM)."
May Berberine impedes the DNA damage repair to inhibit colorectal cancer by regulating the SOX17/TCF4/PIM3 axis. (Molecular genetics and genomics : MGG, 2026, PMID 42201413): "First, we found that BBR demonstrated a dose-dependent inhibition of the viability of CRC cells."
Jun Ameliorative Effect and Mechanism of Huoxiang-Huanglian on TNBS-Induced Inflammatory Bowel Disease in Zebrafish. (Biomedical chromatography : BMC, 2026, PMID 42124338): "Molecular docking confirmed strong binding (below -5.00 kJ/mol) of HH components like retusin and berberine to ODC1."
May Liposomal design and shear shielding of colloidal matrices control drug release. (International journal of pharmaceutics, 2026, PMID 42119862): "Two berberine-loaded liposomal formulations with distinct drug-dipalmitoylphosphatidylglycerol electrostatic interaction strengths showed significantly different release profiles under laminar flow, low-shear environment (f2 = 40.32) but converged under high shear (f2 = 68.31), and closely approached the permeation of free berberine, indicating that drug-membrane affinity governs release under mild shear but is overridden at higher mechanical stress."
Apr Berberine enhances cisplatin efficacy in ehrlich ascites carcinoma via modulation of apoptotic pathway and efferocytosis. (Scientific reports, 2026, PMID 42049890): "Berberine, a bio-alkaloid from medicinal plants, shows therapeutic potential against various ailments, including cancer."
Jun Integrative network pharmacology and molecular simulation analysis reveals the therapeutic potential of Coscinium fenestratum alkaloids against SARS-CoV-2. (Biochemical and biophysical research communications, 2026, PMID 41967451): "Even though Coscinium fenestratum is known to contain alkaloids like berberine, palmatine, and tembetarine, and traditional medicine says it can change the immune system, no systematic computational analysis has looked at its multi-target potential against SARS-CoV-2 host dependency factors that are important for viral replication and immunopathology."
Mar Nose-to-brain delivery of berberine-loaded nanoemulsion: Amelioration of brain targeting, behavioral, pharmacokinetic, and biodistribution insights for Alzheimer's intervention. (Biomaterials advances, 2026, PMID 41875607): "Berberine (BER), a benzylisoquinoline alkaloid, has garnered attention for its multifaceted pharmacological properties, including pronounced antioxidant, anti-inflammatory, and neuroprotective effects."